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Abstract 
The bromodomain and extraterminal (BET) protein BRD4 regulates gene expression via 
recruitment of transcriptional regulatory complexes to acetylated chromatin. Pharmacological 
targeting of BRD4 bromodomains by small-molecule inhibitors has proven to be an effective 
means to disrupt aberrant transcriptional programs critical for tumor growth and/or survival. 
Herein, we report AZD5153, a potent, selective, and orally available BET/BRD4 bromodomain 
inhibitor possessing a bivalent binding mode. Unlike previously described monovalent 
inhibitors, AZD5153 ligates two bromodomains in BRD4 simultaneously. The enhanced avidity 
afforded through bivalent binding translates into increased cellular and antitumor activity in 
preclinical hematologic tumor models. In vivo administration of AZD5153 led to tumor stasis 
or regression in multiple xenograft models of Acute Myeloid Leukemia (AML), Multiple 
Myeloma (MM), and Diffuse Large B-cell Lymphoma (DLBCL). The relationship between 
AZD5153 exposure and efficacy suggests that prolonged BRD4 target coverage is a primary 
efficacy driver. AZD5153 treatment markedly impacts transcriptional programs of MYC, E2F, 
and mTOR. Of note, mTOR pathway modulation is associated with cell line sensitivity to 
AZD5153. Transcriptional modulation of MYC and HEXIM1 was confirmed in AZD5153-
treated human whole blood, thus supporting their use as clinical pharmacodynamic 
biomarkers. This report establishes AZD5153 as a highly potent, orally available BET/BRD4 
inhibitor and provides rationale for clinical development in hematologic malignancies.  
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Introduction 
BRD4 is a member of the bromodomain and extraterminal (BET) family of chromatin reader 
proteins. BET proteins feature characteristic tandem N-terminal bromodomains that function 
to interact with N-acetyl lysine residues on histones and nuclear proteins (1-4). Bromodomain-
mediated interactions localize BRD4 to discrete chromosomal locations, facilitating the 
recruitment of transcriptional regulatory complexes, such as the general initiation cofactor 
Mediator and the Positive Transcription Elongation Factor b (P-TEFb) (5-7). Studies involving 
chromatin immunoprecipitation coupled with DNA-sequencing (ChIP-seq) have revealed a 
highly asymmetric genome-wide binding pattern of BRD4, with most chromatin-bound BRD4 
localizing to enhancer elements. In particular, BRD4 has been shown to predominately bind 
enhancer elements, which are important for cell-type specification and oncogenesis (8, 9). 
 
The discovery of lysine-mimetic small molecules capable of disrupting the chromatin binding 
activity of BET bromodomains was a crucial step towards uncovering the cancer supporting 
activity of BRD4 (10-12). In hematologic malignancies such as AML, MM and DLBCL, the 
misregulated expression of hematopoietic transcription factors is particularly important. BRD4 
maintains and facilitates oncogenic transcription by interacting directly with transcription 
factors, and/or co-occupying transcription factor gene control loci, contributing to cancer cell 
proliferation and survival. For example, in AML, BRD4 chromatin occupancy is enriched at 
enhancer and promoter regions and highly correlated with the distribution of PU.1, FLI1, ERG, 
C/EBPα, C/EBPβ, and MYB (13). BRD4 inhibition interferes with the functional output of these 
lineage-specific transcription factors, and thereby inhibits AML maintenance. In MM the 
survival of malignant plasma cells is dependent on MYC transcriptional activity. MYC 
deregulation in MM can occur through gene translocation, amplification and overexpression 
(14, 15). In this setting BRD4 inhibition disrupts MYC activity and results in MM cell cycle 
arrest and senescence (16). DLBCL is a biologically and clinically heterogeneous disease, 
which is similarly typified by the activation of lineage-specific and growth-associated 
transcription factors including NF-B, BCL6, p53, and MYC (17-20). BRD4 inhibition 
downregulates oncogenic MYC and E2F transcriptional pathways, resulting in antiproliferative 
effects across DLBCL subtypes (21). Based on this and other work, several drug candidates 
targeting BRD4/BET have progressed into clinical trials to treat Nut Midline Carcinoma (NMC), 
AML, Myelodysplastic Syndromes (MDS), MM, DLBCL, Glioblastoma Multiforme, and other 
solid tumors. 
 
We recently described the discovery of BET bromodomain inhibitors that are chemically 
distinct from the commonly described benzodiazepine-based scaffold and capable of a novel 
bivalent binding mode (22).  A dedicated medicinal chemistry campaign led to the discovery 
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of a BET inhibitor clinical candidate AZD5153 (23). In this study, we characterize the in cell 
bivalent binding mode of AZD5153 and demonstrate the cellular and pharmacological 
advantages achieved through the unique biophysical properties of AZD5153 using AML, MM, 
and DLBCL as model systems.  
 
 
Materials and Methods 
Cell lines and Reagents 
Most of cell lines were purchased from ATCC or DSMZ and a few obtained from academic 
laboratories from 2006 to 2014, and cultured according to providers’ instructions (detailed 
information in Supplementary Table 1).  Cell lines were authenticated using DNA fingerprinting 
short-tandem repeat (STR) assays and confirmed to be free of bacterial and viral 
contaminations by IDEXX (Westbrook, ME).  All cell lines were used within15 passages, and 
less than 6 months. Antibodies used for western blot analysis were from Cell Signaling 
Technology (Danvers, MA): Anti-cMyc (#5605), anti-GAPDH (#2118), anti-phospho-p70S6K 
(T389/412) (#9209), anti-p70S6K (#2708), anti-PRAS40 (#2610), anti-phospho-S6 
(S235/236) (#4856), anti-S6 (#2217), anti-phospho-4EBP1 (S65) (#9451), and anti-4EBP1 
(#9644).   
 
Bioluminescence Resonance Energy Transfer (BRET) NanoBRET assay 
The BRD4 NanoBRET assays have been previously described (24).  Briefly, the expression 
construct of Histone H3.3-Halotag (NM_002107), was co-transfected with either NanoLuc-
BRD4 full-length (1-1362) (060885), NanoLuc-BRD4 full-length N433F mutant, or NanoLuc-
N-terminal BRD4-BD1 (amino acids 44-168) expression vector into HCT116 cells.  Cells were 
then seeded into 384-well plates and treated with various concentrations of compounds.  
Plates were read after 18 hours of compound treatment. 
 
Immuno-fluorescent assays for BRD4 chromatin displacement 
The Immuno-fluorescent assays have been previously described (24). Briefly, BRD4 foci were 
stained by using anti-BRD4 antibody (Sigma Aldrich, HPA015 HPA015055) and secondary 
anti-rabbit antibody labeled with Alexa Fluor 488. The specificity of BRD4 antibody was verified 
by siRNA BRD4 knockdown in U2OS cells (24).  Image acquisition was carried out by 
ImageXpress MicroXL High Content Screening System (Molecular Devices) and data analysis 
by MetaXpress (Molecular Devices). 
 
MYC Flow assay  
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MM.1S cells were plated in 96-well plates at 200k cells/well and treated with serial 
concentrations of compound 1 hour after plating and grown for 16 hours at 37°C.  Cells were 
transferred into a 96-well V-bottom plate and fixed sequentially with 2% paraformaldehyde for 
10 minutes at 37°C followed with 90% cold methanol for 10 minutes on ice.  Cells were washed 
and blocked in incubation buffer (PBS+0.5%BSA) for 10 minutes and incubated with anti-cMyc 
primary antibody (1:200) at RT for 1 hour. Cells were washed twice and then stained with 
Alexa 488 conjugated anti-rabbit IgG (1:1000, Cell Signaling technology #4412) for 30 minutes 
at RT and washed again. The pellet was resuspended in incubation buffer and analyzed by 
flow cytometer (BD FACSCalibur) using the FL-1 detector. Data was analyzed using FlowJo 
software V7. Live cell population was selected by gating on FCS/SSC and Geo Mean 
fluorescence of FL-1 signal was used to calculate IC50. 
 
Immunoblots 
Cells were plated at 1 × 106 cells/ml in 6-well plates, treated with compounds at various 
concentrations for 4 or 24 hours. Crude lysate was prepared with 1 x SDS lysis buffer (60 mM 
Tris-HCl pH 6.8, 1% SDS, and 10% glycerol). For xenograft tumors, tissues were 
homogenized in buffer (20 mM Tris pH 8.0, 150 mM NaCI2, 1 % NP-40, in 10 ml of lysis buffer 
supplement with 100 µl of Phosphatase Inhibitor Cocktail2 (Sigma Cat # P5726-5ML), 100 µl 
of Phosphatase Inhibitor Cocktail3 (Sigma Cat #P0044-5ML), 1 tablet of complete protease 
inhibitor cocktail (Roche #11836153001). Samples with 20 µg of total protein were loaded and 
western blots were run following typical procedures.  
 
Cell anti-proliferation and viability assays 
Sixty-one cell lines were cultured in appropriate medium. Optimal 384-well seeding densities 
were pre-measured for linear growth over 72 hours. 30 µl cells/well were seeded in black, flat 
bottom 384-well plates and treated with compounds for 72 hours.  The viable cells were 
measured using Alamar Blue reagents following manufacture’s protocol (Invitrogen). The 
percent net growth is calculated by normalizing against the no-drug controls, and the GI50 
value, the concentration that causes 50% net growth inhibition, was calculated using 
GraphPad Prism 6. 
Viability assay was performed following the same protocol as the anti-proliferation assay but 
differed in data treatment.  Absolute number of remaining viable cells, instead of percent net 
growth, was determined after 72 hours of compound treatment. Cell viability IC50 value was 
obtaining by fitting the raw data points with sigmoidal nonlinear regression and IC50 curves 
were plotted using GraphPad Prism6. 
 
FACS apoptosis assay 
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Apoptosis was analyzed by flow cytometry using CellEvent Caspase 3/7 Green detection 
reagent (ThermoFisher, #C10423). MV-4-11, MM.1S and K562 cells were pre-treated with 
AZD5153 or I-BET762 for 48 hours in culture media. Cells were collected and stained with 5 
µM final concentration of CellEvent for 30 minutes at 37ºC. Flow cytometry was done on a BD 
Fortessa using the Blue laser and FITC filter set. Gating and data analysis was done using 
FlowJo V7.0 software.  
 
RNA-sequencing 
After AZD5153 (200 nM) or vehicle treatment of hematological cell lines (AML - KG1A, 
MOLM13, MV-4-11, OCIAML2; MM - IM9, MM.1S, MOLP8, OPM2, RPMI8226; DLBCL - 
OCILY19, WILL2) for 24 hours, RNA isolation, cDNA library generation, and sequencing to 
12M reads on the Illumina HighSeq was carried out at Q2 Solutions (Morrisville, NC). Bcbio-
nextgen was used to process FastQ files, perform quality control, alignment to genome build 
hg19, and quantify transcription expression based on Ensembl annotation. EdgeR [19910308] 
version 3.12.0 was used to identify differentially expressed genes using trimmed mean of M 
values for normalization and the exactTest method for differential expression. All RNAseq data 
were deposited at GEO (GSE85840). 
 
Gene Set Enrichment Analysis 
Gene set enrichment analysis (GSEA) [16199517, 12808457] was performed using the GSEA 
software (Broad Institute, Cambridge, MA). A signal-to-noise preranked list of gene expression 
changes was generated from log2 FPKM values for vehicle and AZD5153-treated cell lines 
and compared to the hallmarks (h.all.v5.0.symbols.gmt) and transcription factor targets 
(c3.tft.v5.0.symbols.gmt) gene sets from MSigDb [16199517] using default parameters. 
 
Reverse phase protein microarray (RPPA) for proteomic profiling 
Proteomic profiling was carried out using high-density protein dot blot-based immunoassay 
system provided by Theranostics (Gaithersburg, MD). Cells were treated with 200 nM 
AZD5153 for 24 hour, protein lysates prepared following Theranotics’ protocol, and samples 
shipped to Theranostics to perform the array study. A total of 182 endpoints were assessed 
by immunostaining with corresponding antibodies. Data acquisition, quality control, and 
normalization were performed by Theranostics. AZD5153-modulated protein targets were 
identified by performing a paired, two-sided Student's T-test between DMSO and AZD5153 
treated samples 
 
Quantitative PCR  
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Cell pellets containing ~1x106 cells or ~10 mg of tumor tissue were collected. RNA was 
extracted using an RNAeasy mini kit and manufacturer’s protocol (Qiagen, cat# 74104). RNA 
was converted to cDNA with a High Capacity RT kit following manufacturer’s protocol (Applied 
Biosystems, cat#4368814). PCR was performed using Taqman Gene Expression Master Mix 
(Applied Biosystems, cat#4369016) with 300 ng of cDNA and taqman probes (Applied 
Biosystems, # MYC- Hs00153408_m1, #HEXIM1-Hs00538918_s1, and #GAPDH control- 
4352934E) on ABI Prism 7900HT instrument. 
 
Efficacy and PK/PD studies in vivo xenograft models 
Female CB17 SCID and SCID beige mice were obtained from Charles River (Wilmington, MA) 
and NSG mice from Jackson Labs (Bar Harbor, ME). All animals were used in compliance 
with protocols approved by the Institutional Animal Care and Use Committees of AstraZeneca. 
Between 5x106 and 107 tumor cells were implanted into appropriate host mice and tumor 
volume monitored twice weekly. Tumor volume (mm3) is measured with calipers and 
calculated as (W2 x L) / 2, where W is width and L is length.  Tumor growth inhibition is 
calculated as (RTVcontrol − RTVtreatment)*100) / (RTVcontrol − 1), where RTVcontrol is the geometric 
mean of relative tumor volume of control group and RTVtreatment the treatment group. Relative 
tumor volume is calculated using final tumor volume/initial tumor volume for individual animals. 
Statistical significance was evaluated using a one-tailed Student t test. Eight to ten mice per 
group were used for efficacy and three mice per group for PD studies. Mice were treated with 
either vehicle (0.5% hydroxymethylcellulose, 0.1% Tween80) or AZD5153 by oral gavage 
mini-pump infusion.  For continuous administration of AZD5153, compound was solubilized in 
20% v/v DMSO/60% v/v HP-B-CD in water, loaded into a mini pump (Alzet, model 2002) and 
implanted subcutaneously in mice. Tumor fragments collected were snap frozen or fixed in 
10% buffered formalin. Blood samples were collected from the same mice and stabilized in 
EDTA. Plasma concentrations were determined by liquid chromatography/ tandem mass 
spectrometry method. 
 
Immunohistochemical (IHC) analysis  
Formalin fixed tumors were subjected to processing through graded ethanol, xylene and 
paraffin, embedded into paraffin blocks and 3 μm sections were cut for assays. IHC was run 
with an optimized protocol on the Ventana Discovery XT using anti- Myc primary rabbit 
polyclonal antibody (Millipore #06-340) at a 1:200 dilution, biotinylated anti-rabbit secondary 
antibody (Vector Labs #PK-6101) and the DABMap detection kit (Ventana Medical #760-124). 
For cleaved caspase 3, IHC was run with an optimized protocol on the Ventana Discovery XT 
using anti Cleaved Caspase 3 primary rabbit polyclonal antibody (CST-9661) at a 1:5000 
dilution, biotinylated anti-rabbit secondary antibody (Vector Labs #PK-6101) and the DABMap 
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detection kit (Ventana Medical  #760-124). Digital slide images were acquired for both 
antibodies with the Aperio Scanscope XT using a 20X objective. Viable tumor areas were 
manually selected in Aperio Imagescope (version 11), and percent positive nuclei were 
quantified using a modified Nuclear Algorithm (version 9). 
 
Modulation of PD Biomarkers in human whole blood 
Whole blood was collected from six healthy donors and incubated with DMSO or 100 nM 
AZD5153 for 2 hours at 37°C.  The whole blood was transferred to PAXgene RNA tubes (BD 
Diagnostics), incubated for 2 hours at room temperature for RNA stabilization and stored at -
20°C until RNA extraction.  RNA extraction was performed using PAXgene Blood RNA kits 
(Qiagen) according to manufacturer’s instructions.  Total RNA was then quantified, reverse 
transcribed and used as template for quantitative PCR using primers (ABI) specific for MYC 
and HEXIM1.  Data was normalized using GAPDH as the housekeeping gene and converted 
to relative signal (2-ΔCt)*100 to calculate percent of control. 
 
Results 
AZD5153 is a potent BET bromodomain inhibitor possessing a bivalent binding mode 
AZD5153, as shown in Figure 1A, is a potent and selective BET bromodomain inhibitor. 
AZD5153 induces dimerization of Bromodomain 1 construct (BD1) of BRD4 in X-ray co-crystal 
structure (23). Additional biophysical characterization by analytical ultracentrifugation and 
small angle X-ray scattering demonstrated that AZD5153 can bind bivalently, namely, that one 
molecule of AZD5153 binds and ligates two bromodomains in BRD4 (data not shown), in 
contrast to other reported BET inhibitors such as JQ1 and I-BET762 that bind monovalently 
with one molecule binding to each bromodomain in BRD4. 
 
To confirm the in cell binding mode of AZD5153, we utilized a NanoBRET assay to monitor 
the interaction of BRD4 with chromatin using Halo-tagged histone H3 and a Nanoluciferase 
fusion protein with either the BD1 domain alone (BD1-BRD4) or a full-length BRD4 construct 
(FL-BRD4)  (Figure 1B) (24). AZD5153 demonstrated a remarkable enhancement in potency 
for the displacement of full-length BRD4 relative to BD1, with IC50 values of 5.0 nM and 1.6 
µM, for FL-BRD4 and BD1-BRD4, respectively (Figure 1C). In contrast, the monovalent 
inhibitor, I-BET762, displaced both BD1 and full-length protein with comparable potency (200 
nM for BD1-BRD4 and 79 nM for FL-BRD4) (22). Further evidence of simultaneous 
engagement of BD1 and BD2 by AZD5153 was obtained by analogous experiments 
comparing wild-type FL-BRD4 to a bromodomain N433F mutant in which the BD2 function 
was abolished. AZD5153 demonstrated a drastically reduced IC50 value of 1.4 µM in displacing 
mutant BRD4 from chromatin, in contrast to 8.7 nM IC50 for wild-type protein (Supplementary 
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Figure 1A). In comparison, the monovalent inhibitor JQ1 showed a similar chromatin 
displacement dose-response between the mutant and wild-type protein (Supplemental Figure 
1B).  Taken together, these data provide compelling evidence that the bivalent binding mode 
is the binding mechanism for AZD5153 in cells. 
 
 
Avidity of bivalent binding leads to enhanced cellular potency with increased BRD4 
displacement from chromatin and MYC modulation  
We previously established a quantitative immuno-fluorescent assay to examine BRD4 
chromatin displacement by measuring the disruption of BRD4 foci which are resulted from 
highly asymmetric binding of BRD4 to the enhancer regions (22). In this assay, AZD5153 
potently disrupted BRD4 foci in U2OS cells with an IC50 value of 1.7 nM (Figure 1D-E).  In 
contrast, the monovalent inhibitor I-BET762 had an IC50 of 36.0 nM in the same assay (Figure 
1E).  
 
To assess whether enhanced BRD4 bromodomain binding activity translated into modulation 
of downstream targets, we examined MYC protein modulation in a mixed panel of 14 
hematologic tumor cell lines. AZD5153 efficiently down-regulated MYC protein levels across 
the cell line panel irrespective of their sensitivity to AZD5153 (Supplementary Figure 2). 
AZD5153 was more potent than the monovalent inhibitor I-BET762 in down-regulating MYC 
protein, with 33 nM of AZD5153 sufficient in reducing MYC to basal levels, whereas significant 
MYC remaining with 300 nM of I-BET762 in MM1.S cells (Figure 1F). This observation was 
further confirmed by quantitative flow cytometry, which determined a MYC protein modulation 
IC50 of 5.4 nM for AZD5153, compared to an IC50 of 329 nM for I-BET762 (Figure 1G).  
  
Acute Myeloid Leukemia, Multiple Myeloma, and Diffuse Large B cell lymphoma cell 
lines are highly sensitive to AZD5153 
In order to assess the anti-proliferative activity of AZD5153 in hematologic cancers, we tested 
a cell-line panel comprised of 61 AML, MM and DLBCL cell lines. As shown in Figure 2A, all 
cell lines tested exhibited exquisite sensitivity towards AZD5153 (GI50 < 150 nM), with the 
majority of lines tested having a GI50 < 25 nM. We hypothesized that the bivalent binding mode 
of AZD5153 could result in more robust target engagement and suppression of down-stream 
effector pathways, collectively leading to an enhanced reduction in cell viability in select 
hematological cancer subtypes. To test this hypothesis, five cell lines were treated AZD5153 
or I-BET762 for 72 hours and cell viability was measured. Across all five cell lines, the 
AZD5153 IC50 values were an average of 18-fold more potent than I-BET762 (Supplementary 
Figure 3), with representative cell viability IC50 curves shown in Figure 2B-D.  
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Although treatments with both drugs essentially eliminated all viable cells in MM cell lines as 
evidenced by the higher drug concentration points in the dose-response curves  (Figure 2C 
and Max% cell kill in Supplementary Figure 4), AZD5153 reduced the level of remaining viable 
cells in KARPAS422, RSV411, and JURKAT lines when the maximal drug effect of AZD5153 
and I-BET762 demonstrated a plateau (Figures 2B and 2D, and Max% cell kill in 
Supplementary Figure 4). We deployed a flow cytometry assay to quantitatively measure 
caspase-3 positive cell populations in these cell lines to understand if a differential induction 
of apoptosis explained the difference observed in the cell viability assays. Unlike I-BET762, 
AZD5153 potently induces substantial apoptosis at 100 nM in MV-4-11 and MM.1S cells 
(Figure 2E-F).  In summary, the avidity of bivalent target engagement by AZD5153 translated 
into deeper cellular responses in hematological cell lines. 
  
AZD5153 modulates E2F, MYC, and mTOR transcriptional programs  
To gain further understanding of the underlying cellular mechanism of phenotypic response 
and to facilitate biomarker discovery, we performed RNA-sequencing on a panel of 
hematologic cancer cell lines (AML n=4, MM n=5, DLBCL n=2) after treatment with AZD5153 
(200 nM) or DMSO vehicle for 24 hours (GSE85840). RNA-sequencing analysis revealed 172 
genes (109 down- and 63 up-regulated genes) that were significantly modulated (log2 fold 
change > 1 and false discovery rate (FDR) < 0.05) across the cell line panel (Figure 3A and 
Supplementary Table 1). Consistent with previous studies of BET inhibition, differential 
expression of HEXIM1, MYC, BCL2, FOSL1, and E2F1 was observed in select or multiple cell 
line types (16, 25-27). Gene Ontology (GO) analysis (28) was performed on the 109 uniformly 
down-regulated transcripts by AZD5153. Genes involved in G1/S transition and cell cycle 
progression were highly enriched, suggesting that the intersecting genes function in core 
cellular processes (Supplementary Figure 3). We used Gene Set Enrichment Analysis (GSEA) 
(29, 30) to gain a more comprehensive understanding of AZD5153 inhibitory effects on 
biological hallmarks and transcription factors using all cell line and tumor-specific data ranked 
by differential expression. Significant gene sets identified in at least one comparison (FDR < 
0.1) were ranked and represented by a heat map. Similar correlating hallmarks were noted 
across all tumor types and included transcriptional targets of MYC, E2F transcription factors, 
and mTOR signaling components (Figures 3B – 3E). 
  
Repression of mTOR signaling is an AZD5153 sensitivity correlate 
In order to determine the consequences of BRD4 inhibition on protein levels, we used reverse-
phase protein array (RPPA) technology to quantitatively examine the expression of 182 total- 
and phospho-proteins following 24 hours of AZD5153 treatment (200 nM) in K562, IM9, 
MOLP8, MV-4-11, and OCILY19 cell lines (Supplementary Table 2). To identify protein 
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modulation that correlated with sensitivity to AZD5153, we segregated cell lines into resistant 
(K562, IM9) and sensitive (MOLP8, MV-4-11, OCILY19) groups based on a GI50 cutoff of 100 
nM. Interestingly, RPPA revealed that cell lines sensitive to AZD5153 exhibited a marked 
decrease in the level of mTOR-pathway associated proteins following AZD5153 treatment 
(Figure 4A). Selective down-regulation of p-p70S6K, PRAS40, and p-4EBP1 in AZD5153-
sensitive cell lines was confirmed by western blot with multiple doses of AZD5153 (Figure 4B). 
In contrast, MYC modulation was observed in both sensitive and resistant cell lines (Figure 
4B), suggesting that MYC downregulation was not sufficient to modulate cell survival. These 
data suggest that in hematologic malignancies, mTOR pathway downregulation may serve as 
an appropriate biomarker of sensitivity to BRD4 inhibitors such as AZD5153. 
 
AZD5153 demonstrates potent anti-tumor activity in hematologic xenograft models  
In order to assess the in vivo activity of AZD5153, we explored the effects of dosing AZD5153 
in AML, MM, and DLBCL xenografts. MLL-fusion leukemia has previously been shown to be 
dependent on BRD4 (26, 31). Thus we chose a xenograft model of MV-4-11, an AML cell line 
that harbors an MLL-AF4 fusion oncogene, for initial in vivo efficacy experiments.  A dose-
dependent tumor growth inhibition (TGI) was observed for 1, 2.5, and 5 mg/kg daily (QD) oral 
doses of AZD5153, ranging from 72% TGI for 1 mg/kg to regression for 5mg/kg (Figure 5A 
and Supplementary Figure 5). A parallel experiment was carried out to further understand the 
dose-efficacy relationship for the lower end. Oral QD doses of 0.07, 0.36, and 0.72 mg/kg 
produced 16%, 23% and 53% TGI, respectively (Supplementary Figure 5). To determine if 
AZD5153 had anti-tumor activity beyond MLL-fusion AML, we tested it in additional xenograft 
models with known MYC or BRD4 linkage representing segments of MM, AML, and DLBCL. 
Treatment with 5 mg/kg QD, or a lower dose of 3.6 mg/kg for KARPAS422, resulted in 61% 
tumor regression in KMS11, 100% TGI in MOLP-8, 98% TGI in RS4;11, and 95% TGI in 
KARPAS-422 xenograft models (Figures 5A-C and Supplementary Figure 5). Interestingly, 
the AML model KG1a demonstrates similar in vitro potency to AZD5153 as the above models; 
however, it is less sensitive to AZD5153 in vivo. For example, a higher dose of 10 mg/kg QD 
resulted in moderate TGI of 74% (Figure 2A and Supplementary Figure 5). Understanding the 
difference between sensitivity in vitro and in vivo for KG1a would require further investigation. 
These data demonstrate AZD5153 is efficacious in a range of hematologic malignancies in 
vivo. 
 
Duration of BRD4 inhibition is the driver for efficacy and sustained BRD4 inhibition led 
to near complete tumor regression  
In an effort to understand if increased daily target coverage could drive greater efficacy, we 
evaluated QD, BID, and continuous dosing delivered via a subcutaneous mini-pump in MV-4-
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11 tumor-bearing mice for 14 or 24 days. Increased efficacy was observed when AZD5153 
was given BID at 1.25 or 2.5 mg/kg (split dose) compared to 2.5 or 5 mg/kg QD 
(Supplementary Figure 5). The enhanced efficacy with BID dosing suggests that the duration 
of BRD4 target coverage is the driver for efficacy in the MV-4-11 tumor model.  Consistent 
with this notion, near complete regression (97%) of MV-4-11 tumors was achieved after 14 
days of continuous delivery of AZD5153 at 12.8 mg/kg/week by mini-pump, with half of the 
dose at 6.4 mg/kg/week still resulting in tumor stasis (Figure 5D). A higher oral dose of 5 
mg/kg/daily, equivalent to 35 mg/kg/week, is needed to achieve a comparable efficacy to the 
6.4 mg/kg/week continuous dose (Figure 5D). The steady and prolonged BRD4 inhibition 
achieved with the mini-pump was associated with increased apoptosis in the tumors compared 
with daily oral dosing after 7 days of treatment (Figure 5E-F). However, 12.8 mg/kg/week mini-
pump group, that was twice the efficacious dose of 6.4 mg/kg/week, was accompanied by 
significant body weight loss with an average weight loss of 10% observed. Taken together, 
these results support that the duration of BRD4 inhibition is the primary driver for in vivo 
efficacy, and additional dose/schedule investigation is needed to determine an appropriate 
balance of target coverage and tolerability to maximize the therapeutic benefit. 
 
Pharmacodynamic evaluation in xenograft models and human whole blood supports 
MYC and HEXIM1 as biomarkers for AZD5153 inhibition 
To understand the pharmacokinetic (PK)/PD relationship of AZD5153, MYC mRNA and 
protein levels were measured by quantitative PCR (qPCR) and western blot. The 
concentration of AZD5153 was also measured in the plasma of the corresponding mouse after 
a single oral dose of 2.5, 5, or 10 mg/kg in MV-4-11 xenografts. All three doses induced 
significant modulation of MYC mRNA and protein over the first 8 hours but largely recovered 
by 16 hours (Figures 6A and 6D). There was an inverse correlation between AZD5153 
concentration in plasma and MYC mRNA levels in tumors (Figure 6A). Significant inhibition of 
MYC mRNA was achieved with free plasma concentration as low as 0.1 µM of AZD5153 in 
mice with MV-4-11 tumors. The MYC mRNA levels returned to baseline as AZD5153 was 
cleared from the plasma. In contrast, HEXIM1 mRNA was up-regulated by AZD5153 treatment 
and had a similar but inverse PK/PD relationship (data not shown). An example of such a 
relationship is shown in Figure 6F, when mRNA levels of MYC and HEXIM1 were determined 
at 2 hours post the 5mg/kg dose, MYC mRNA was down-regulated by about 80% whereas 
HEXIM1 mRNA was up-regulated by 400% (Figure 6F). 
 
To confirm MYC protein modulation by AZD5153 and understand the heterogeneity within the 
tumors, immunohistochemistry (IHC) was performed in MV-4-11 tumors after 20 mg/kg 
dosing.  As shown in Figure 6B and 6C, the vehicle treated tumor samples have 40% of cells 
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with strong or medium MYC staining with the remaining 60% of cells having weak or no MYC 
staining. Acute oral administration of 20 mg/kg AZD5153 greatly reduced the number of cells 
with strong or medium intensity of MYC (97% and 75% reduction, respectively) at 2 hours post 
dosing. Correlating with PK, MYC staining intensity began to recover at 8 hours, the last time 
point taken in the study (Figures 6B and 6C). Interestingly, there were a significant number of 
cells with medium MYC staining remaining throughout the time points, highlighting the 
heterogeneity nature of response, a phenomenon that is frequently observed in the treatment 
of patient tumors. 
 
Due to the limited availability of paired tumor biopsy samples during clinical development of 
novel agents, PD assessment with tumor tissue is not always achievable. Therefore we 
evaluated AZD5153 induced mRNA expression changes in whole blood as a surrogate PD 
endpoint. To identify potential clinical PD biomarkers, the mRNA expression of MYC and 
HEXIM1 genes were evaluated in human whole blood from healthy volunteers. Treatment with 
100 nM AZD5153 for 2 hours resulted in 42% decrease of MYC and 240% increase of HEXIM1 
mRNA (Figure 6E), similar to observation in MV-4-11 tumor tissue (Figure 6F). These data 
support the evaluation of these two biomarkers, together with other novel candidates that are 
under active investigation (manuscript in preparation), as potential human whole blood PD 
biomarkers in clinical trials. 
 
 
Discussion 
Herein, we assessed the characteristics of AZD5153, a novel BET bromodomain inhibitor. The 
bivalent binding mode of AZD5153 sets it apart from previously described BET bromodomain 
inhibitors. Mechanistically, the simultaneous ligation of both BRD4 bromodomains by 
AZD5153 allows for efficient displacement of BRD4 from chromatin at lower drug 
concentrations. This unique biophysical property translates into enhanced in vitro and in vivo 
pharmacological activity.  
 
In the hematologic tumor setting, our comparative efficacy studies with QD, BID and 
continuous dosing of AZD5153 have revealed that duration of target coverage is the primary 
driver for in vivo efficacy. Twice daily dosing with the split QD dose mitigated the issue of fast 
clearance of AZD5153 from the mouse system and provided longer duration of target inhibition 
translating into better efficacy. We enhanced these findings by employing mini-pump drug 
infusion, which eliminates PK fluctuations, and provides consistent target inhibition. Compared 
to daily oral dosing, less than one fifth of AZD5153 was needed per week via mini-pump to 
achieve comparable efficacy. Furthermore, our data indicate Cmax does not play a significant 
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role in driving AZD5153 efficacy. Namely, there was a greater than 12 fold difference in Cmax 
between 5 mg/kg/daily oral and 6.4 mg/kg/week mini-pump infusion. Unfortunately, enhanced 
efficacy achieved through prolonged target inhibition was often accompanied by significant 
body weight loss, which we used as a surrogate for gastrointestinal toxicity for BET inhibitors 
in mice. However, there remains a therapeutic index at lower doses using continuous infusion 
or a daily oral schedule, thus allowing for anti-tumor activity without concomitant bodyweight 
loss.  Sustained BRD4 inhibition for a period of 2-3 days could lead to in vitro cell death of MV-
4-11 cancer cells via apoptosis, suggesting that an intermittent schedule is sufficient to deliver 
efficacy. Further investigation is needed to validate if such a schedule can sufficiently induce 
tumor cell death, while minimizing toxicity within normal tissues. Moreover, BET bromodomain 
inhibitors may have different scheduling requirements in solid tumor settings, owing to 
differences in tumor biology and microenvironment. A systematic investigation of both dose 
and schedule will be required to find the appropriate balance of drug exposure, efficacy, and 
tolerability for the myriad of disease subtypes for which BRD4 is being prosecuted as a cancer 
drug target. Ongoing clinical studies will no doubt be critical to define the optimal use of the 
BET bromodomain inhibitors. 
  
Our gene expression analysis characterized the transcriptional response induced by AZD5153 
in AML, MM, and DLBCL. Consistent with previously described studies examining BET 
bromodomain inhibitors, we observed significant modulation of MYC and E2F gene programs. 
However, our study is the first, to our knowledge, to reveal a significant modulation of an 
mTOR gene signature in these tumor types. Furthermore, we demonstrated that modulation 
of the mTOR signaling correlates with sensitivity to AZD5153 in cell lines we studied whereas 
MYC levels do not.  Our data suggest that modulation of the mTOR pathway, which is widely 
de-regulated in many hematological cancers, contributes to the broad anti-cancer phenotype 
that we and others have observed for BET inhibitors in preclinical hematological cancer 
models. Consistent with this observation, the clinical candidate BET inhibitor, OTX015, 
exhibits synergy when combined with Everolimus in DLBCL (32). We speculate that 
downregulation of mTOR signaling components may serve as a correlative biomarker for 
future clinical studies of AZD5153 and/or other clinical candidate BET bromodomain inhibitors.  
 
Both MYC mRNA and protein exhibited a concentration-dependent decrease in response to 
AZD5153 in both cell and in vivo models of hematological malignancies. Furthermore, 
inhibition of MYC mRNA was also observed in treated human whole blood and corresponded 
with an induction of HEXIM1 expression, supporting the use of these readouts as potential 
clinical biomarkers of target engagement for AZD5153. In the clinical setting, the use of human 
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whole blood as a means to demonstrate target engagement could be beneficial, especially 
when paired tumor biopsies are not available.   
 
In summary, AZD5153 is a novel BET bromodomain inhibitor with a bivalent binding mode. 
The unique biophysical properties of AZD5153 offer potency and pharmacological advantages 
over traditional monovalent BET bromodomain inhibitors. Based on potent in vivo anti-tumor 
activity, AZD5153 is a promising drug candidate for the treatment of hematological 
malignancies.  
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Figure Legends 
Figure 1. AZD5153 is a potent BET bromodomain inhibitor possessing a bivalent 
binding mode.  (A) Chemical structure of AZD5153.  (B) Schematic of cellular nano-BRET 
assay system using full-length BRD4 (FL-BRD4) or BD1 domain only BRD4 (BD1-BRD4) with 
a NanoLuc tag and histone H3.3 with a HaloTag in HCT116 cells.  (C) Dose-response curves 
of AZD5153 displacing FL-BRD4 or BD1-BRD4 from histone H3.3 after 18 hours of treatment. 
(D) Formation of bright foci resulted from highly level of BRD4 bindings to the enhancer 
regions visualized by immuno-fluorescent staining in U2OS cells, and foci disruption by 4 
hours treatment of 10 nM AZD5153. (E) Dose-response curves of BRD4 foci inhibition with 
AZD5153 and a monovalent inhibitor I-BET762. (F) Western blots of MYC protein modulation 
by various concentrations of AZD5153 and I-BET762 in MM.1S cells with 4 hours of compound 
treatment. (G) MYC modulation dose-response curves of AZD5153 and I-BET762 in MM.1S 
cells by quantitative flow cytometry analysis. 
 
Figure 2. AZD5153 exhibits broad anti-proliferative activity against hematological 
cancer cell lines. (A) Bar plot of GI50 values across a mixed panel of AML (black), MM 
(orange) and DLBCL (red) hematological cancer cell lines following 72 hours treatment with 
AZD5153. Of note, *RS4;11 in AML panel is actually an acute lymphoblastic leukemia (ALL) 
line.  B-D) Head-to-head comparison of cell viability dose-response curves of AZD5153 and 
I-BET762 in the indicated cell lines after 72 hours treatment. (E-F) Apoptosis induction was 
assessed by measuring caspase-3 positive cell populations at various concentrations of 
AZD5153 and I-BET762 in the indicated cell lines 48 hours after compound treatment. 
 
Figure 3. RNA-seq analysis reveals down-regulation of MYC, E2F, and mTOR target 
gene transcription by AZD5153. (A) Venn diagram representation of the most down- and 
up-regulated genes (FDR < 0.05 and log2 fold change > 1) following AZD5153 treatment for 
24 hours in AML, MM, and DLBCL cell lines.  (B) Heat maps of FDR (q < 0.01) values from 
GSEA of MSigDb transcription factor targets. Gene sets correlating with the AZD5153 
phenotype are depicted. (C) Representative GSEA plots depicting gene sets most associated 
with AZD5153 down-regulation from MSigDb.  (D) Heat maps of FDR (q < 0.01) values from 
GSEA of hallmarks gene set collections. (E) Representative GSEA plots depicting gene sets 
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most associated with AZD5153 down-regulation from transcription factor target collections in 
all hematological cell lines. 
 
Figure 4. Repression of mTOR signaling is an AZD5153 sensitivity correlate. (A) 
Unsupervised clustering heat map of mTOR-related total and phospho-proteins across five 
hematological cell lines from Reverse Phase Protein Array analysis. Bar at the top of the heat 
map indicates whether a cell line was sensitive (yellow) or resistant (blue) to AZD5153. 
Individual protein values were generated by calculating the ratio of protein modulation at 24 
hour between DMSO and AZD5153 (200 nM) treatments. Turquoise, AZD5153-induced 
decreased expression; red, AZD5153-induced increased expression. Data are scaled 
according to z scores by protein. (B) Western blot analysis of the change of protein level of 
select mTOR pathway signaling molecules and MYC by four concentrations of AZD5153 (0, 
2, 20, and 200 nM) after 24 hours of compound treatment across 5 hematological cell lines.  
Bar at the top of the Western blot indicates whether a cell line was sensitive (yellow) or 
resistant (blue) to AZD5153. Separation mark in the middle of Western blot indicates this is a 
combined blot from two gels. Only one representative GAPDH loading control is shown. 
 
Figure 5. AZD5153 is active in hematological xenograft models. (A-C) Tumor growth 
curves with treatment of AZD5153 vs. vehicle in representative tumor xenograft models of 
AML, MM, and DLBCL. Mice were treated daily with vehicle or oral dose of 3.6 or 5 mg/kg 
AZD5153. (D) Comparative anti-tumor effects with oral dose of 5 mg/kg/daily, continuous 
delivery of 6.4 mg/kg/wk or 12.8 mg/kg/wk via mini-pump, and vehicle. Black lines, vehicle-
treated mice; blue, purple, and green lines, AZD5153-treated mice (E) Quantified cleaved 
caspase 3 intensity from immuno-histochemistry (IHC) in MV-4-11 tumors after 7 days of 
treatment. (F) Representative images of IHC used for image analysis showing increase in 
apoptoic cells after AZD5153 treatment  
 
Figure 6. AZD5153 modulates MYC and HEXIM1 in AML xenograft tumors and human 
whole blood. (A) Relationship of MYC mRNA levels in MV-4-11 tumors and AZD5153 
concentration in mouse plasma at three dose levels of AZD5153. Each bar represents an 
individual mouse. (B) Immunohistochemistry (IHC) quantifying percentage of MV-4-11 tumor 
cells with different levels of MYC staining intensity (weak, medium and strong) over time after 
a single oral 20 mg/kg dose of AZD5153. (C) Representative MYC IHC images used for 
analysis. The heterogeneity of MYC staining intensity is apparent in each tumor section. (D) 
Western blot for MYC expression in same tumors used for mRNA analysis shown in A. (E) 
Modulation of MYC and HEXIM1 mRNA in human whole blood after in vivo treatment with 
100nM AZD5153. Blood samples were obtained from normal healthy volunteers. Error bars ± 
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SEM. (F) Modulation of MYC and HEXIM1 mRNA in MV-4-11 xenograft tumor tissue 2 hours 
post the 5 mg/kg oral dose. 
 
